Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 5Active not recruiting 5Not yet recruiting 4Withdrawn 1Terminated 1Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1

Interventions

pembrolizumab 20Magnetic Resonance Spectroscopy 13Specimen Handling 12Cyclophosphamide 11fludarabine 10Radiotherapy 9Biopsy 9atezolizumab 7Nivolumab 7Radiation 6Gemcitabine 5fludarabine phosphate 4aldesleukin 4Prednisone 4Etoposide 4Cytarabine 4Cisplatin 4Carboplatin 4Blood Specimen Collection 4ALT-803 4lenvatinib 3avelumab 3X-Rays 3Vincristine 3Surveys and Questionnaires 3Rituximab 3Phantoms, Imaging 3Paclitaxel 3Oxaliplatin 3Lenalidomide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Hyaluronoglucosaminidase × 1 year × Clear all
NCT07082270 2026-05-15

Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma

Roswell Park Cancer Institute

Phase 1 Withdrawn
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡